UBS Group
VRXA

UBS Group’s Veraxa Biotech AG VRXA Stock Holding History

UBS Group’s Portfolio VRXA Stock Details VRXA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Buy
+157,237
New +$1.26M ﹤0.01% 6559

Other funds holding VRXA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.47% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's VRXA Position: Q2 2026 in Review

UBS Group opened a new position in Veraxa Biotech AG (VRXA) in Q2 2026: 157,237 shares worth $296K. The stake represents ﹤0.01% of the portfolio and ranks #6559 among its holdings.

6 funds tracked by Wall St. Rank hold VRXA as of Q2 2026.

  • UBS Group held 157,237 shares of Veraxa Biotech AG worth $296K as of Q2 2026.
  • Veraxa Biotech AG was a new UBS Group position in Q2 2026.
  • Veraxa Biotech AG made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6559 holding.
  • 6 funds tracked by Wall St. Rank held Veraxa Biotech AG as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.